Zacks: Brokerages Expect Hologic, Inc. (NASDAQ:HOLX) Will Announce Earnings of $0.61 Per Share
Equities analysts expect Hologic, Inc. (NASDAQ:HOLX) to post $0.61 earnings per share for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for Hologic’s earnings, with the lowest EPS estimate coming in at $0.60 and the highest estimate coming in at $0.62. Hologic posted earnings of $0.58 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 5.2%. The business is expected to announce its next quarterly earnings results after the market closes on Wednesday, July 31st.
According to Zacks, analysts expect that Hologic will report full-year earnings of $2.42 per share for the current year, with EPS estimates ranging from $2.40 to $2.44. For the next year, analysts expect that the firm will post earnings of $2.61 per share, with EPS estimates ranging from $2.57 to $2.67. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Hologic.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, May 1st. The medical equipment provider reported $0.58 EPS for the quarter, topping the consensus estimate of $0.57 by $0.01. Hologic had a negative net margin of 0.32% and a positive return on equity of 26.73%. The firm had revenue of $818.40 million during the quarter, compared to analyst estimates of $806.99 million. During the same quarter in the previous year, the business posted $0.53 EPS. Hologic’s revenue was up 3.7% on a year-over-year basis.
NASDAQ HOLX traded up $1.16 during mid-day trading on Thursday, reaching $48.50. 2,016,921 shares of the stock were exchanged, compared to its average volume of 1,783,193. The business has a 50 day simple moving average of $47.29. Hologic has a 1 year low of $37.47 and a 1 year high of $49.78. The stock has a market cap of $12.62 billion, a P/E ratio of 21.75, a P/E/G ratio of 2.17 and a beta of 0.72. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 1.31.
In related news, insider Peter J. Valenti III sold 4,545 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $44.07, for a total value of $200,298.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Horan Capital Advisors LLC. bought a new position in shares of Hologic during the 1st quarter worth approximately $33,000. First Interstate Bank acquired a new stake in shares of Hologic during the first quarter valued at about $40,000. Quadrant Capital Group LLC lifted its stake in Hologic by 1,363.2% in the first quarter. Quadrant Capital Group LLC now owns 995 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 927 shares during the last quarter. Bronfman E.L. Rothschild L.P. lifted its stake in Hologic by 90.1% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,194 shares of the medical equipment provider’s stock worth $49,000 after acquiring an additional 566 shares during the last quarter. Finally, SevenBridge Financial Group LLC lifted its stake in Hologic by 172.0% in the second quarter. SevenBridge Financial Group LLC now owns 1,205 shares of the medical equipment provider’s stock worth $58,000 after acquiring an additional 762 shares during the last quarter. 96.38% of the stock is owned by hedge funds and other institutional investors.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: How to Profit and Limit Losses With Stop Orders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.